Related Experiment Video
Updated: Mar 28, 2026
05:18
Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
Published on: May 26, 2023
2.0K
Recent Advances in Hydrocortisone Replacement Treatment.
Endocrine Development
|December 20, 2015
Summary
Conventional hydrocortisone replacement therapy for cortisol deficiency is inadequate. Novel physiological approaches, like modified-release formulations and continuous infusions, show promise for improving patient outcomes.
Area of Science:
- Endocrinology
- Chronobiology
- Pharmacology
Background:
- Synthetic glucocorticoids significantly impact medicine, but conventional hydrocortisone replacement for cortisol deficiency remains inadequate.
- Standard treatment fails to mimic cortisol's physiological circadian rhythm, impacting biological processes and the circadian timing system.
- Circadian misalignment from non-physiological glucocorticoid treatment may contribute to increased mortality, poor quality of life, and metabolic complications in adrenal insufficiency.
Purpose of the Study:
- To review advancements in physiological cortisol replacement therapy.
- To assess the potential of novel hydrocortisone formulations and delivery methods.
- To highlight the need for further research on long-term outcomes.
Main Methods:
- Review of recent developments in modified-release hydrocortisone formulations (Chronocort®, Plenadren®).
- Evaluation of continuous subcutaneous hydrocortisone infusions.
- Analysis of initial clinical and biochemical studies on these novel regimens.
Main Results:
- Modified-release formulations and continuous infusions represent progress in physiological cortisol replacement.
- Initial studies demonstrate promising clinical and biochemical improvements in patients.
- These novel approaches aim to synchronize glucocorticoid delivery with the body's natural rhythm.
Conclusions:
- Physiological replacement of cortisol is crucial for managing adrenal insufficiency.
- Novel delivery systems offer improved therapeutic potential over conventional hydrocortisone.
- Larger studies are required to confirm long-term benefits in children and adults.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
624
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
624
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K
01:26COPD: Management Using Bronchodilators and Corticosteroids
1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
932
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
932
01:22Drug Delivery: Miscellaneous Routes
970
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
970
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
664
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
664